CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
“MSK-ACCESS could potentially be used for patients whose tumor tissue isn’t available or is difficult to biopsy, or if MSK-IMPACT on a tumor biopsy fails to produce informative results because too few tumor cells were in the biopsy, which primarily happens in people with advanced metastatic cancer,” Michael Berger, PhD, associate director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, said in a press release.
Memorial Sloan Kettering Cancer Center,
800-525-2225
Pages: 1 2